ABSTRACT
The midbrain reticular formation (MRF) is a mosaic of diverse GABAergic and glutamatergic neurons that have been associated with a variety of functions, including sleep regulation. However, the molecular characteristics and development of MRF neurons are poorly understood. As the transcription factor, Gata2 is required for the development of all GABAergic neurons derived from the embryonic mouse midbrain, we hypothesized that the genes expressed downstream of Gata2 could contribute to the diversification of GABAergic neuron subtypes in this brain region. Here, we show that Gata2 is required for the expression of several GABAergic lineage-specific transcription factors, including Nkx2-2 and Skor2, which are co-expressed in a restricted group of post-mitotic GABAergic precursors in the MRF. Both Gata2 and Nkx2-2 function is required for Skor2 expression in GABAergic precursors. In the adult mouse and rat midbrain, Nkx2-2-and Skor2-expressing GABAergic neurons locate at the boundary of the ventrolateral periaqueductal gray and the MRF, an area containing REM-off neurons regulating REM sleep. In addition to the characteristic localization, Skor2+ cells increase their activity upon REM-sleep inhibition, send projections to the dorsolateral pons, a region associated with sleep control, and are responsive to orexins, consistent with the known properties of midbrain REM-off neurons.
Subject(s)
GABAergic Neurons , Sleep, REM , Animals , GABAergic Neurons/metabolism , GATA2 Transcription Factor/genetics , GATA2 Transcription Factor/metabolism , Homeobox Protein Nkx-2.2/metabolism , Mesencephalon , Mice , Nerve Tissue Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Rats , Sleep/physiology , Sleep, REM/physiology , Transcription Factors/genetics , Transcription Factors/metabolismABSTRACT
Endemic human coronaviruses (hCoVs) are common causative agents of respiratory tract infections, affecting especially children. However, in the ongoing SARS-CoV-2 pandemic, children are the least affected age-group. The objective of this study was to investigate the magnitude of endemic hCoVs antibodies in Finnish children and adults, and pre-pandemic antibody cross-reactivity with SARS-CoV-2. Antibody levels against endemic hCoVs start to rise at a very early age, reaching to overall 100% seroprevalence. No difference in the antibody levels was detected for OC43 but the magnitude of 229E-specific antibodies was significantly higher in the sera of children. OC43 and 229E hCoV antibody levels of children correlated significantly with each other and with the level of cross-reactive SARS-CoV-2 antibodies, whereas these correlations completely lacked in adults. Although none of the sera showed SARS-CoV-2 neutralization, the higher overall hCoV cross-reactivity observed in children might, at least partially, contribute in controlling SARS-CoV-2 infection in this population.
Subject(s)
Antibodies, Viral/blood , COVID-19/epidemiology , Coronavirus 229E, Human/immunology , Coronavirus OC43, Human/immunology , SARS-CoV-2/immunology , Adult , Antibody Specificity , COVID-19/immunology , COVID-19/virology , Child , Child, Preschool , Cross Reactions , Endemic Diseases , Enzyme-Linked Immunosorbent Assay , Finland/epidemiology , Humans , Infant , Middle Aged , Seroepidemiologic StudiesABSTRACT
Tegmental nuclei in the ventral midbrain and anterior hindbrain control motivated behavior, mood, memory, and movement. These nuclei contain inhibitory GABAergic and excitatory glutamatergic neurons, whose molecular diversity and development remain largely unraveled. Many tegmental neurons originate in the embryonic ventral rhombomere 1 (r1), where GABAergic fate is regulated by the transcription factor (TF) Tal1. We used single-cell mRNA sequencing of the mouse ventral r1 to characterize the Tal1-dependent and independent neuronal precursors. We describe gene expression dynamics during bifurcation of the GABAergic and glutamatergic lineages and show how active Notch signaling promotes GABAergic fate selection in post-mitotic precursors. We identify GABAergic precursor subtypes that give rise to distinct tegmental nuclei and demonstrate that Sox14 and Zfpm2, two TFs downstream of Tal1, are necessary for the differentiation of specific tegmental GABAergic neurons. Our results provide a framework for understanding the development of cellular diversity in the tegmental nuclei.
Subject(s)
GABAergic Neurons/metabolism , Glutamic Acid/metabolism , Rhombencephalon/metabolism , Tegmentum Mesencephali/metabolism , Animals , Cell Differentiation , Cell Lineage , DNA-Binding Proteins/metabolism , Dorsal Raphe Nucleus/metabolism , Embryo, Mammalian/cytology , Female , Forkhead Box Protein O1/metabolism , Homeodomain Proteins/metabolism , Male , Mice, Inbred C57BL , Neural Stem Cells/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Notch/metabolism , SOXB2 Transcription Factors/metabolism , Signal Transduction/drug effects , T-Cell Acute Lymphocytic Leukemia Protein 1/metabolism , Transcription Factors/metabolismABSTRACT
Tissue and vessel wall stiffening alters endothelial cell properties and contributes to vascular dysfunction. However, whether extracellular matrix (ECM) stiffness impacts vascular development is not known. Here we show that matrix stiffness controls lymphatic vascular morphogenesis. Atomic force microscopy measurements in mouse embryos reveal that venous lymphatic endothelial cell (LEC) progenitors experience a decrease in substrate stiffness upon migration out of the cardinal vein, which induces a GATA2-dependent transcriptional program required to form the first lymphatic vessels. Transcriptome analysis shows that LECs grown on a soft matrix exhibit increased GATA2 expression and a GATA2-dependent upregulation of genes involved in cell migration and lymphangiogenesis, including VEGFR3. Analyses of mouse models demonstrate a cell-autonomous function of GATA2 in regulating LEC responsiveness to VEGF-C and in controlling LEC migration and sprouting in vivo. Our study thus uncovers a mechanism by which ECM stiffness dictates the migratory behavior of LECs during early lymphatic development.
Subject(s)
GATA2 Transcription Factor/metabolism , Gene Expression Regulation, Developmental , Lymphangiogenesis/genetics , Lymphatic Vessels/physiology , Animals , Cell Movement/genetics , Endothelial Cells/physiology , Female , GATA2 Transcription Factor/genetics , Gene Expression Profiling , Gene Knockdown Techniques , Humans , Lymphatic Vessels/cytology , Male , Mice , Mice, Transgenic , Primary Cell Culture , RNA, Small Interfering/metabolism , Vascular Endothelial Growth Factor C/metabolism , Vascular Endothelial Growth Factor Receptor-3/genetics , Vascular Endothelial Growth Factor Receptor-3/metabolismABSTRACT
The transcription factor GATA2 is required for expansion and differentiation of hematopoietic stem cells (HSCs). In mesenchymal stem cells (MSCs), GATA2 blocks adipogenesis, but its biological relevance and underlying genomic events are unknown. We report a dual function of GATA2 in bone homeostasis. GATA2 in MSCs binds near genes involved in skeletal system development and colocalizes with motifs for FOX and HOX transcription factors, known regulators of skeletal development. Ectopic GATA2 blocks osteoblastogenesis by interfering with SMAD1/5/8 activation. MSC-specific deletion of GATA2 in mice increases the numbers and differentiation capacity of bone-derived precursors, resulting in elevated bone formation. Surprisingly, MSC-specific GATA2 deficiency impairs the trabecularization and mechanical strength of bone, involving reduced MSC expression of the osteoclast inhibitor osteoprotegerin and increased osteoclast numbers. Thus, GATA2 affects bone turnover via MSC-autonomous and indirect effects. By regulating bone trabecularization, GATA2 expression in the osteogenic lineage may contribute to the anatomical and cellular microenvironment of the HSC niche required for hematopoiesis.
Subject(s)
Bone and Bones/metabolism , GATA2 Transcription Factor/genetics , Gene Expression Regulation, Developmental/genetics , Hematopoietic Stem Cells/cytology , Mesenchymal Stem Cells/cytology , Osteogenesis/genetics , 3T3 Cells , Animals , Binding Sites/genetics , Bone Marrow Cells/metabolism , Cell Differentiation/genetics , Cell Line , Cellular Microenvironment/genetics , Fractures, Bone/genetics , GATA2 Deficiency/genetics , GATA2 Deficiency/pathology , Male , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Nuclear Proteins/metabolism , Smad1 Protein/metabolism , Smad5 Protein/metabolism , Smad8 Protein/metabolism , Transcription Factors/metabolismABSTRACT
BACKGROUND: Rotavirus (RV) vaccination using RotaTeq® vaccine exclusively was introduced into Finnish National Immunization Program (NIP) in 2009, and soon reached high (≥90%) coverage. Since mid-2013, all stool samples from laboratory diagnosed cases of RV gastroenteritis in the entire country have been typed. METHODS: 364 RV positive stool samples collected from clinical laboratories over a 2-year period were G- and P-typed using RT-PCR, and the results were confirmed by sequencing. In addition, the genome segment encoding for VP6 was sequenced to distinguish between wild-type and vaccine origin (bovine) RVs. RESULTS: RV winter epidemic seasons 2013-2014 and 2014-2015 lasted until July each. The age distribution of RV cases showed two unusual clusters: one in children 6-16 years of age, too old to have been vaccinated in NIP, and the other in elderly over 70 years of age. In children, diverse genotypes were observed without any obvious predominance. The most common ones were G1P[8] (30.0%), G2P[4] (22.4%), G9P[8] (15.8%), G3P[8] (12.2%) and G4P[8] (11.2%). The genotype distribution was not different among vaccinated and unvaccinated children. Most cases in the elderly were associated with G2P[4]. CONCLUSIONS: Even at high vaccine coverage and high effectiveness of RV vaccine, RV activity continues to persist, particularly in unvaccinated older children. RV genotypes show greater diversity than before RV vaccinations. We conclude that RV disease can be controlled but not eliminated by vaccinations. Herd-protection in long-term follow-up may be less than at the start of RV vaccinations.
Subject(s)
Gastroenteritis/epidemiology , Gastroenteritis/prevention & control , Rotavirus Infections/epidemiology , Rotavirus Infections/prevention & control , Rotavirus Vaccines/administration & dosage , Vaccination/statistics & numerical data , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , Feces/virology , Female , Finland/epidemiology , Gastroenteritis/virology , Genotype , Humans , Infant , Infant, Newborn , Male , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Rotavirus/classification , Rotavirus/genetics , Rotavirus/isolation & purification , Rotavirus Infections/virology , Sequence Analysis, DNA , Vaccines, Attenuated/administration & dosage , Young AdultABSTRACT
KEY POINTS: The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also. BACKGROUND: Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up. METHODS: Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as "cases" and rotavirus-negative children as "controls." Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001-2006) and post-NIP seasons (2009-2013). RESULTS: The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%-98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons. CONCLUSIONS: Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children.
Subject(s)
Gastroenteritis/prevention & control , Rotavirus Infections/prevention & control , Rotavirus Vaccines/therapeutic use , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Finland/epidemiology , Gastroenteritis/epidemiology , Gastroenteritis/virology , Hospitalization/statistics & numerical data , Humans , Infant , Infant, Newborn , Population Surveillance , Reverse Transcriptase Polymerase Chain Reaction , Rotavirus/genetics , Rotavirus Infections/diagnosis , Rotavirus Infections/epidemiology , Rotavirus Infections/virology , Seasons , Treatment Outcome , Vaccines, Attenuated/therapeutic useABSTRACT
Serotonergic and glutamatergic neurons of the dorsal raphe regulate many brain functions and are important for mental health. Their functional diversity is based on molecularly distinct subtypes; however, the development of this heterogeneity is poorly understood. We show that the ventral neuroepithelium of mouse anterior hindbrain is divided into specific subdomains giving rise to serotonergic neurons as well as other types of neurons and glia. The newly born serotonergic precursors are segregated into distinct subpopulations expressing vesicular glutamate transporter 3 (Vglut3) or serotonin transporter (Sert). These populations differ in their requirements for transcription factors Gata2 and Gata3, which are activated in the post-mitotic precursors. Gata2 operates upstream of Gata3 as a cell fate selector in both populations, whereas Gata3 is important for the differentiation of the Sert+ precursors and for the serotonergic identity of the Vglut3+ precursors. Similar to the serotonergic neurons, the Vglut3-expressing glutamatergic neurons, located in the central dorsal raphe, are derived from neural progenitors in the ventral hindbrain and express Pet1 Furthermore, both Gata2 and Gata3 are redundantly required for their differentiation. Our study demonstrates lineage relationships of the dorsal raphe neurons and suggests that functionally significant heterogeneity of these neurons is established early during their differentiation.
Subject(s)
Dorsal Raphe Nucleus/cytology , GATA2 Transcription Factor/genetics , GATA3 Transcription Factor/genetics , Neurogenesis/genetics , Rhombencephalon/embryology , Serotonergic Neurons/cytology , Amino Acid Transport Systems, Acidic/metabolism , Animals , Mice , Mice, Knockout , Neural Stem Cells/cytology , Neurogenesis/physiology , Neuroglia/cytology , Rhombencephalon/physiology , Serotonin Plasma Membrane Transport Proteins/metabolism , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology , Transcription Factors/biosynthesisABSTRACT
BACKGROUND: Universal rotavirus (RV) vaccination with RotaTeq was introduced into National Immunization Programme (NIP) of Finland in September 2009. We have previously reported the reduction of RV gastroenteritis (GE) cases in the first 2 years after RV vaccination in NIP in Finland. METHODS: In Tampere University Hospital, a 2-year survey of acute GE (AGE) in children was conducted before NIP in the years 2006 to 2008. This was followed by a similar prospective survey in years 2009 to 2011 and now extended to years 2012 to 2014. Stool samples from children examined in the hospital for AGE were analyzed by real-time polymerase chain reaction assays for RV and norovirus, and positive samples were typed by sequencing. RESULTS: The proportion of RVGE of all AGE cases decreased from 52% (421 of 809 cases) in pre-NIP years to 26% (86 of 330 cases) in post-NIP years 2009 to 2011 falling to 12% (40 of 347 cases) in 2012 and 2014. The hospitalizations for RVGE were reduced by 90% and the outpatient clinic visits also by 90% in 2012 to 2014, compared with pre-NIP year; all AGE cases were reduced by 59%. Norovirus was a major causative agent of AGE in the post-NIP period, accounting for 34% of the cases in 2009 to 2011 and 29% in 2012 to 2014. CONCLUSIONS: RV vaccination in NIP has led to a major reduction of RVGE cases seen in hospital with no resurgence in 5 years after NIP. A high coverage of RV vaccination will maintain RV activity at a low level but not eliminate wild-type RV circulation.
Subject(s)
Rotavirus Infections/epidemiology , Rotavirus Infections/prevention & control , Rotavirus Vaccines , Rotavirus/genetics , Adolescent , Age Factors , Child , Child, Preschool , Finland/epidemiology , Gastroenteritis/epidemiology , Gastroenteritis/prevention & control , Gastroenteritis/virology , Genotype , Humans , Infant , Infant, Newborn , Prospective Studies , Real-Time Polymerase Chain Reaction , Rotavirus Infections/virology , Vaccines, AttenuatedABSTRACT
Transforming growth factor ß (TGFß) is a potent inhibitor of hematopoietic stem and progenitor cell proliferation. However, the precise mechanism for this effect is unknown. Here, we have identified the transcription factor Gata2, previously described as an important regulator of hematopoietic stem cell function, as an early and direct target gene for TGFß-induced Smad signaling in hematopoietic progenitor cells. We also report that Gata2 is involved in mediating a significant part of the TGFß response in primitive hematopoietic cells. Interestingly, the cell cycle regulator and TGFß signaling effector molecule p57 was found to be upregulated as a secondary response to TGFß. We observed Gata2 binding upstream of the p57 genomic locus, and importantly, loss of Gata2 abolished TGFß-stimulated induction of p57 as well as the resulting growth arrest of hematopoietic progenitors. Our results connect key molecules involved in hematopoietic stem cell self-renewal and reveal a functionally relevant network, regulating proliferation of primitive hematopoietic cells.
Subject(s)
Cell Proliferation/drug effects , Cyclin-Dependent Kinase Inhibitor p57/genetics , GATA2 Transcription Factor/genetics , Hematopoietic Stem Cells/drug effects , Smad4 Protein/genetics , Transforming Growth Factor beta/pharmacology , Animals , Cell Line , Cell Proliferation/genetics , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p57/metabolism , GATA2 Transcription Factor/metabolism , Gene Expression Profiling/methods , Gene Regulatory Networks/drug effects , Gene Regulatory Networks/genetics , HEK293 Cells , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/metabolism , Humans , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Models, Genetic , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , Smad4 Protein/metabolismABSTRACT
Local inhibitory GABAergic and excitatory glutamatergic neurons are important for midbrain dopaminergic and hindbrain serotonergic pathways controlling motivation, mood, and voluntary movements. Such neurons reside both within the dopaminergic nuclei, and in adjacent brain structures, including the rostromedial and laterodorsal tegmental nuclei. Compared with the monoaminergic neurons, the development, heterogeneity, and molecular characteristics of these regulatory neurons are poorly understood. We show here that different GABAergic and glutamatergic subgroups associated with the monoaminergic nuclei express specific transcription factors. These neurons share common origins in the ventrolateral rhombomere 1, where the postmitotic selector genes Tal1, Gata2 and Gata3 control the balance between the generation of inhibitory and excitatory neurons. In the absence of Tal1, or both Gata2 and Gata3, the GABAergic precursors adopt glutamatergic fates and populate the glutamatergic nuclei in excessive numbers. Together, our results uncover developmental regulatory mechanisms, molecular characteristics, and heterogeneity of central regulators of monoaminergic circuits.
Subject(s)
Cell Differentiation , Cell Nucleus/metabolism , Dopaminergic Neurons/cytology , Mesencephalon/cytology , Neural Inhibition , Animals , Biomarkers/metabolism , Chickens , Embryo, Mammalian/metabolism , Female , Forkhead Transcription Factors/metabolism , GABAergic Neurons/cytology , GATA Transcription Factors/metabolism , Glutamates/metabolism , Male , Mice, Inbred C57BL , Mice, Inbred ICR , Mitosis , Models, Biological , Repressor Proteins/metabolism , Serotonin/metabolism , Substantia Nigra/cytology , Ventral Tegmental Area/cytology , gamma-Aminobutyric Acid/metabolismABSTRACT
Gata2 is a zinc finger transcription factor that is important in hematopoiesis and neuronal development. However, the roles of Gata2 in the mesenchymal lineages are poorly understood. In vitro studies suggest that Gata2 modulates adipocyte differentiation and mesenchymal stem cell (MSC) proliferation. To systematically determine the in vivo functions of Gata2 in the MSC lineage commitment and development, we have generated three mouse models in which Gata2 is specifically deleted in MSCs, adipocytes, or osteoblasts. During the MSC expansion stage, Gata2 promotes proliferation and attenuates differentiation; thereby Gata2 loss in MSCs results in enhanced differentiation of both adipocytes and osteoblasts. During the differentiation stage, Gata2 also plays MSC-independent roles to impede lineage commitment; hence, Gata2 loss in adipocyte or osteoblast lineages also augments adipogenesis and osteoblastogenesis, respectively. These findings reveal Gata2 as a crucial rheostat of MSC fate to control osteoblast and adipocyte lineage development.
Subject(s)
Adipocytes/metabolism , Cell Differentiation/genetics , Cell Proliferation/genetics , GATA2 Transcription Factor/genetics , Mesenchymal Stem Cells/metabolism , Osteoblasts/metabolism , Adipocytes/cytology , Adipogenesis/genetics , Animals , Cell Lineage , Gene Expression Regulation , Male , Mesenchymal Stem Cells/cytology , Mice , Osteoblasts/cytology , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Corpus callosum (CC) is the largest commissural tract in mammalian brain and it acts to coordinate information between the two cerebral hemispheres. During brain development CC forms at the boundary area between the cortex and the septum and special transient neural and glial guidepost structures in this area are thought to be critical for CC formation. In addition, it is thought that the fusion of the two hemispheres in the septum area is a prerequisite for CC formation. However, very little is known of the molecular mechanisms behind the fusion of the two hemispheres. Netrin1 (NTN1) acts as an axon guidance molecule in the developing central nervous system and Ntn1 deficiency leads to the agenesis of CC in mouse. Here we have analyzed Ntn1 deficient mice to better understand the reasons behind the observed lack of CC. We show that Ntn1 deficiency leads to defects in neural, but not in glial guidepost structures that may contribute to the agenesis of CC. In addition, Nnt1 was expressed by the leptomeningeal cells bordering the two septal walls prior to fusion. Normally these cells are removed when the septal fusion occurs. At the same time, the Laminin containing basal lamina produced by the leptomeningeal cells is disrupted in the midline area to allow the cells to mix and the callosal axons to cross. In Ntn1 deficient embryos however, the leptomeninges and the basal lamina were not removed properly from the midline area and the septal fusion did not occur. Thus, NTN1 contributes to the formation of the CC by promoting the preceding removal of the midline leptomeningeal cells and interhemispheric fusion.
Subject(s)
Agenesis of Corpus Callosum/genetics , Agenesis of Corpus Callosum/pathology , Corpus Callosum/embryology , Meninges/abnormalities , Nerve Growth Factors/deficiency , Age Factors , Animals , Axons/pathology , Calbindin 2/metabolism , Corpus Callosum/pathology , Disease Models, Animal , Embryo, Mammalian , Galactosides/genetics , Galactosides/metabolism , Gene Expression Regulation, Developmental/genetics , Glial Fibrillary Acidic Protein/genetics , Glial Fibrillary Acidic Protein/metabolism , Indoles/metabolism , Meninges/cytology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nerve Growth Factors/genetics , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Netrins , RNA, Messenger , Transcription Factors/genetics , Transcription Factors/metabolismABSTRACT
Heterozygous germline mutations in the zinc finger transcription factor GATA2 have recently been shown to underlie a range of clinical phenotypes, including Emberger syndrome, a disorder characterized by lymphedema and predisposition to myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). Despite well-defined roles in hematopoiesis, the functions of GATA2 in the lymphatic vasculature and the mechanisms by which GATA2 mutations result in lymphedema have not been characterized. Here, we have provided a molecular explanation for lymphedema predisposition in a subset of patients with germline GATA2 mutations. Specifically, we demonstrated that Emberger-associated GATA2 missense mutations result in complete loss of GATA2 function, with respect to the capacity to regulate the transcription of genes that are important for lymphatic vessel valve development. We identified a putative enhancer element upstream of the key lymphatic transcriptional regulator PROX1 that is bound by GATA2, and the transcription factors FOXC2 and NFATC1. Emberger GATA2 missense mutants had a profoundly reduced capacity to bind this element. Conditional Gata2 deletion in mice revealed that GATA2 is required for both development and maintenance of lymphovenous and lymphatic vessel valves. Together, our data unveil essential roles for GATA2 in the lymphatic vasculature and explain why a select catalogue of human GATA2 mutations results in lymphedema.
Subject(s)
GATA2 Transcription Factor/metabolism , Lymphatic Vessels/embryology , Lymphedema/embryology , Mutation , Animals , Enhancer Elements, Genetic , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , GATA2 Transcription Factor/genetics , Gene Deletion , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , K562 Cells , Lymphatic Vessels/pathology , Lymphedema/genetics , Lymphedema/pathology , Mice , NFATC Transcription Factors/genetics , NFATC Transcription Factors/metabolism , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolismABSTRACT
Studies investigating the magnitude and breath of protective immune responses after primary and subsequent norovirus infections in pediatric populations are limited. We investigated incidence of norovirus infections and serological responses in a child from longitudinal stool and serum samples collected from birth to 2 years of age. Four consecutive infections with distinct genotypes of norovirus were detected. Serum antibodies were genotype-specific offering no protection to reinfection with heterologous virus. CONCLUSION: This study describes norovirus-specific serological responses in a child with four consecutive norovirus infection during the first 2 years of life. The response is type-specific and does not protect from a subsequent infection with a heterologous virus. WHAT IS KNOWN: ⢠Correlates of protection to norovirus infection and disease are not yet determined, and most of the presently available data concern adult population. WHAT IS NEW: ⢠This manuscript describes serological immune responses after primary and subsequent infections in a child during the first 2 years of life.
Subject(s)
Antibodies, Viral/immunology , Caliciviridae Infections/epidemiology , Caliciviridae Infections/immunology , Norovirus/pathogenicity , Antibody Formation/physiology , Genotype , Humans , Incidence , Infant , Infant, Newborn , Longitudinal Studies , Prospective StudiesABSTRACT
Noroviruses (NoVs) are the major causative agents of acute gastroenteritis (AGE) in outbreaks and in sporadic AGE in young children. Since the mid-1990s, NoV genotype GII.4 has been predominant worldwide. New GII.4 variants appear every two to three years, and antigenic variation is focused on the highly variable protruding domain (P2) of the NoV capsid protein which contains the receptor-binding regions. We studied NoV GII.4 variants in cases of endemic AGE in Finnish children from 1998 to 2013. Fecal specimens were collected from cases of AGE followed prospectively in rotavirus vaccine trials from 1998 to 2007, and from children seen at Tampere University Hospital because of AGE from 2006 to 2013. Partial capsid sequences were identified with RT-PCR and sequenced allowing P2 domain alignment and phylogenetic comparison of different GII.4 strains, with virus-like particles (VLPs) developed as candidate vaccines. Of 1495 NoV positive specimens 829 (55%) were of the GII.4 genotype, and altogether twelve GII.4 variants were identified. Identical GII.4 variants were detected in outbreaks of NoVs worldwide. A phylogenetic tree of the amino acid changes in the P2 region showed nine variants that arose over time. Our data indicates that GII.4 continues to be the predominant NoV genotype circulating in the Finnish community, and the changes in the P2 domain over time result in the development of new variants that cause AGE in children. Future NoV vaccines should either induce type specific immunity for each variant or, alternatively, induce broadly reactive protective immunity covering multiple variants.
Subject(s)
Caliciviridae Infections/epidemiology , Caliciviridae Infections/virology , Gastroenteritis/epidemiology , Gastroenteritis/virology , Norovirus/genetics , Adolescent , Antigenic Variation , Caliciviridae Infections/history , Child , Child, Preschool , Disease Outbreaks , Epitopes/immunology , Finland/epidemiology , Gastroenteritis/history , Genes, Viral , Genetic Variation , Genotype , History, 20th Century , History, 21st Century , Humans , Infant , Infant, Newborn , Norovirus/classification , Norovirus/immunology , Phylogeny , Prevalence , Sequence Analysis, DNAABSTRACT
UNLABELLED: Human bocaviruses (HBoVs) may be grouped into respiratory (HBoV1) and enteric (HBoV2-4) types. We examined this association of HBoV types and clinical symptoms in 955 children who had acute gastroenteritis (AGE, n = 172), acute respiratory tract infection (ARTI, n = 545) or symptoms of both (n = 238). Both nasal swab and stool specimens were studied for such patients. HBoV1 DNA was detected in 6.2 % of patients with ARTI and 9.2 % of patients with symptoms of both ARTI and AGE, but in only 1.7 % of patients with AGE alone. In about one half of the cases, HBoV1 was detected concomitantly in nasal swab and stool samples. HBoV2 was found in stool samples of patients with AGE (5.8 %), ARTI (5.1 %) and symptoms of both (5.5 %) but only rarely in nasal swabs. HBoV3 was found in the stools, but not in nasal swabs, in 0.6, 1.1 and 0.8 % of patients with, respectively, AGE, ARTI and both. HBoV4 was not found. All but one HBoV-positive stool sample of AGE patients contained a known gastroenteritis virus (rotavirus, norovirus, sapovirus, astrovirus or enteric adenovirus) that was probably responsible for the symptoms of the respective case. Sera of 30 HBoV-positive patients were available, and IgM antibodies for HBoVs were found in ten cases and HBoV DNA in eight of these. CONCLUSIONS: HBoV2 and HBoV3 were more commonly found in stool than in nasal swab samples, but the findings could not be causally linked with AGE. HBoV1 was commonly found in stool samples during ARTI, with or without gastrointestinal symptoms.
Subject(s)
Child, Hospitalized/statistics & numerical data , Feces/virology , Gastroenteritis/virology , Human bocavirus/isolation & purification , Parvoviridae Infections/virology , Respiratory Tract Infections/virology , Acute Disease , Adolescent , Child , Child, Preschool , Female , Gastroenteritis/epidemiology , Humans , Infant , Male , Parvoviridae Infections/epidemiology , Prospective Studies , Respiratory Tract Infections/epidemiologyABSTRACT
BACKGROUND: Rotavirus (RV) antigenemia and RNAemia are common findings in rotavirus-infected children. Sporadic associations between RV antigenemia and extraintestinal manifestations of RV infection have been observed. We examined the clinical severity of RV gastroenteritis in patients with and without RV antigenemia or RNAemia. METHODS: Stool, serum and whole blood samples were collected from children seen with acute gastroenteritis in Tampere University Hospital and studied for RV using reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay. Only exclusively RV-positive specimens were included into this study. The patients were divided into groups according to RV findings from stool, serum and blood specimens. Clinical manifestations were graded according to 20-point Vesikari scoring system. RESULTS: Of 374 children, 155 (41%) had RV in their stools. Of these 155 children, 105 (67%) were found to have RV RNA in the serum; of those, 94 (90%) had also RV enzyme-linked immunosorbent assay antigen. Thus antigenemia occurred in 61% (94 cases) of RV-infected children all of whom had concomitant RNAemia. Neither antigenemia nor RNAemia were detected in 85 patients with non-RV gastroenteritis. Patients who had RV RNA and RV antigen in both serum and stools were more likely to have a higher level of fever and more severe vomiting than patients who had RV only in stools. G1 genogroup RV was more often associated with RNAemia and antigenemia than other genogroups combined. CONCLUSION: Rotavirus antigenemia and viremia are commonly detected in children hospitalized for RV gastroenteritis and may be associated with increased severity of fever and vomiting.
Subject(s)
Antigens, Viral/blood , Gastroenteritis/virology , Rotavirus Infections/immunology , Rotavirus/isolation & purification , Viremia/immunology , Child , Child, Preschool , Feces/virology , Gastroenteritis/blood , Gastroenteritis/epidemiology , Gastroenteritis/immunology , Humans , Infant , Prospective Studies , RNA, Viral/analysis , RNA, Viral/blood , Rotavirus/immunology , Rotavirus Infections/blood , Rotavirus Infections/epidemiology , Rotavirus Infections/virology , Viremia/blood , Viremia/epidemiology , Viremia/virologyABSTRACT
Neurons using gamma-aminobutyric acid (GABA) as their neurotransmitter are the main inhibitory neurons in the mature central nervous system (CNS) and show great variation in their form and function. GABAergic neurons are produced in all of the main domains of the CNS, where they develop from discrete regions of the neuroepithelium. Here, we review the gene expression and regulatory mechanisms controlling the main steps of GABAergic neuron development: early patterning of the proliferative neuroepithelium, production of postmitotic neural precursors, establishment of their identity and migration. By comparing the molecular regulation of these events across CNS, we broadly identify three regions utilizing distinct molecular toolkits for GABAergic fate determination: telencephalon-anterior diencephalon (DLX2 type), posterior diencephalon-midbrain (GATA2 type) and hindbrain-spinal cord (PTF1A and TAL1 types). Similarities and differences in the molecular regulatory mechanisms reveal the core determinants of a GABAergic neuron as well as provide insights into generation of the vast diversity of these neurons.
Subject(s)
Cell Differentiation/physiology , Central Nervous System/embryology , GABAergic Neurons/cytology , GABAergic Neurons/physiology , Gene Expression Regulation, Developmental/physiology , Models, Biological , Neurogenesis/physiology , Animals , Basic Helix-Loop-Helix Transcription Factors/metabolism , Body Patterning/physiology , Cell Lineage/physiology , Cell Movement/physiology , Central Nervous System/cytology , GABAergic Neurons/classification , Gene Expression Regulation, Developmental/genetics , Humans , Proto-Oncogene Proteins/metabolism , T-Cell Acute Lymphocytic Leukemia Protein 1 , Transcription Factors/metabolismABSTRACT
Midbrain- and hindbrain-derived GABAergic interneurons are critical for regulation of sleep, respiratory, sensory-motor and motivational processes, and they are implicated in human neurological disorders. However, the precise mechanisms that underlie generation of GABAergic neuron diversity in the midbrain-hindbrain region are poorly understood. Here, we show unique and overlapping requirements for the related bHLH proteins Tal1 and Tal2 in GABAergic neurogenesis in the midbrain. We show that Tal2 and Tal1 are specifically and sequentially activated during midbrain GABAergic neurogenesis. Similar to Gata2, a post-mitotic selector of the midbrain GABAergic neuron identity, Tal2 expression is activated very early during GABAergic neuron differentiation. Although the expression of Tal2 and Gata2 genes are independent of each other, Tal2 is important for normal midbrain GABAergic neurogenesis, possibly as a partner of Gata2. In the absence of Tal2, the majority of midbrain GABAergic neurons switch to a glutamatergic-like phenotype. In contrast, Tal1 expression is activated in a Gata2 and Tal2 dependent fashion in the more mature midbrain GABAergic neuron precursors, but Tal1 alone is not required for GABAergic neuron differentiation from the midbrain neuroepithelium. However, inactivation of both Tal2 and Tal1 in the developing midbrain suggests that the two factors co-operate to guide GABAergic neuron differentiation in a specific ventro-lateral midbrain domain. The observed similarities and differences between Tal1/Tal2 and Gata2 mutants suggest both co-operative and unique roles for these factors in determination of midbrain GABAergic neuron identities.